Welcome to our dedicated page for Duluth Holdings SEC filings (Ticker: DLTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Duluth Trading’s irreverent ads may be short, but Duluth Holdings’ SEC disclosures are not. If you need the Duluth Holdings annual report 10-K simplified so you can quickly spot channel-mix trends or marketing spend behind Buck Naked underwear, this page is your starting point.
Stock Titan delivers every filing as soon as it appears on EDGAR and pairs it with AI-powered summaries that translate accounting jargon into plain English. Whether you are hunting for a Duluth Holdings quarterly earnings report 10-Q filing, want the Duluth Holdings 8-K material events explained, or must review the Duluth Holdings proxy statement executive compensation table before voting, our platform surfaces the numbers that move margins and inventory.
- Real-time alerts the moment Duluth Holdings insider trading Form 4 transactions hit the tape
- Instant red-line comparisons for each quarter so your Duluth Holdings earnings report filing analysis is effortless
- Contextual flags that point out liquidity ratios, store roll-out capital, and seasonal inventory swings
Need continuous monitoring? Our engine tracks Duluth Holdings Form 4 insider transactions real-time and highlights patterns in Duluth Holdings executive stock transactions Form 4. Still puzzled? Try understanding Duluth Holdings SEC documents with AI; one click reveals key risks, segment data, and advertising expense trends. Skip the 200-page read—focus on the insights that shape the next trade.
Form 4 Overview: President and Director William C. Emerson reported substantial equity transactions related to Rocket Companies, Inc. (RKT) on 06/30/2025. The filing reflects issuance of Class L-1 and Class L-2 common stock following Rocket’s previously announced Up-C structure collapse.
- Securities acquired: 14,134,895 Class L-1 and 14,134,896 Class L-2 shares to the William C. Emerson Trust; plus 1,413,489 Class L-1 and 1,413,490 Class L-2 shares to each of two family trusts (Nicole Christine Emerson 2012 and Sean William Emerson 2012).
- Consideration: Shares were received at a stated price of $0 per footnote (conversion/recapitalisation, not open-market purchase).
- Transfer & conversion restrictions: L-1 shares locked until 06/30/2026; L-2 shares until 06/30/2027. After lock-ups, each converts 1-for-1 into Class A common stock; automatic conversion occurs upon transfer or if voting power threshold falls.
- Prior holdings: Emerson now indirectly owns 28,269,791 Class L shares through his trust and an additional 5,653,958 Class L shares through family trusts. He directly holds 859,204 Class A shares (includes 453,422 unvested RSUs).
- Corporate context: The Up-C Collapse exchanged Rock Holdings Inc. voting shares for Rocket Class L stock at a fixed 56.54 exchange ratio, simplifying capital structure and migrating legacy owners into Rocket’s equity stack.
The transaction is a non-cash internal recapitalisation; no shares were sold. The filing underscores management’s enlarged economic stake and foreshadows future potential dilution of Class A share count once conversion restrictions lift.
Duluth Holdings Inc. (DLTH) Form 4 filing discloses that Senior Vice President David Homolka purchased 1,000 Class B common shares on 06/30/2025 at $1.42 per share through the company’s Employee Stock Purchase Plan. Following the transaction, Homolka directly owns 274,413 shares, up from 273,413 previously. No derivative securities were reported. The filing signals a modest increase in executive equity ownership but involves a small dollar value (~$1,420), limiting its materiality for investors.
Crescent Biopharma, Inc. (formerly GlycoMimetics, Inc.; Nasdaq ticker now CBIO) filed an extensive Form 8-K to report the closing of its reverse-merger with privately held Crescent Biopharma on 13 June 2025.
Key deal mechanics: immediately prior to closing, GlycoMimetics implemented a 1-for-100 reverse stock split. At the merger’s “First Effective Time,” every Crescent common share converted into 0.1445 share of GlycoMimetics common stock, while Crescent preferred shares became Series A non-voting convertible preferred shares (1 preferred = 1,000 common post-conversion). After applying the exchange ratio and exercising pre-funded warrants, the combined company has 19.55 million common shares on a fully diluted basis (13.89 m outstanding, 2.77 m pre-funded warrants, 2.89 m underlying Series A preferred).
Ownership shift: legacy Crescent security-holders control roughly 97.3 % of the post-merger equity, leaving pre-merger GlycoMimetics holders with only 2.7 %. Support agreements covering 98.4 % of Crescent and 1.7 % of GlycoMimetics shares ensured approval; key Crescent insiders and investors also entered 180-day lock-ups.
Financing: Simultaneous with closing, Crescent raised $200 million (gross) via the sale of 85.5 m common shares and 19.1 m pre-funded warrants at an implied Crescent valuation of $50 million. Proceeds include $40.5 million of previously issued convertible notes that rolled into equity.
Redomestication & rebranding: the company migrated from Delaware to the Cayman Islands via a Plan of Conversion, adopted new Cayman memorandum & articles, and formally changed its name to Crescent Biopharma, Inc. Shares began trading as CBIO on 16 June 2025.
Governance & management: a six-member board was installed (Peter Harwin, chair). Joshua Brumm becomes CEO; other senior hires include Jonathan McNeill (COO/President) and Richard Scalzo (CFO). A 2.35 m-share 2025 Stock Incentive Plan and a 0.20 m-share ESPP were approved. Ernst & Young was dismissed as auditor; PricewaterhouseCoopers was appointed.
Capital structure amendments: authorised common share count increased to 175 m. No fractional shares were issued for the reverse split; cash was paid in lieu.
Implications for investors: the transaction recapitalises the business with $200 m of new cash, positions Crescent’s oncology pipeline inside a Nasdaq-listed vehicle, but massively dilutes prior GLYC holders. Trading liquidity now depends on lock-up expirations and the success of the Crescent pipeline, details of which are incorporated by reference from the S-4.
FAQ
What is the current stock price of Duluth Holdings (DLTH)?
What is the market cap of Duluth Holdings (DLTH)?
What is the core business of Duluth Holdings?
How does the company generate its revenue?
What differentiates Duluth Holdings from other apparel brands?
What types of products does Duluth Holdings offer?
How does the brand communicate its value proposition?
In which markets is Duluth Holdings active?
How does Duluth Holdings position itself within the competitive landscape?
What should investors know about Duluth Holdings' operational strategy?
